Attenuated Acinetobacter Baumannii Vaccine

Acinetobacter baumannii has emerged as an important nosocomial pathogen. There is evidence to suggest that gastrointestinal colonization of A. baumannii in humans precedes the onset of other clinical conditions such as septicemia, pneumonia and wound sepsis, with little known about the interaction of this pathogen with the gastrointestinal (GI) tract. Researchers at UTSA have developed a new attenuated Acinetobacter baumanni mutant from a multi-drug resistant clinical isolate defient in thioredoxin-A (TrxA). This organism exhibits markedly reduced virulence in an I.p. sepsis model and has the potential for use as a live vaccine against A. baumannii infection. Robert Graham (210) 458-8139

Related Blog

Smart, interactive desk

Get ready to take your space management game to the next level with the University of Glasgow’s innovative project! By combining the

Mechanical Hamstring™

University of Delaware Technology Overview This device was created to allow athletes who suffer a hamstring strain to return to the field

Join Our Newsletter

                                                   Receive Innovation Updates, New Listing Highlights And More